Our vision is to impact on patients’ life by advancing the fight against cancer. Based on strong scientific track-records, we focus on priority research areas and provide research expertise covering the most common and/or malignant cancer types representing a health burden in Luxembourg. The department also represents a state-of-the-art training ground for next generation cancer researchers and acts as a reference point for cancer research in Luxembourg.
The main mission of the Department of Cancer Research is to advance the treatment options of cancer and reduce the cancer burden within the Luxembourg population and beyond. We do so through research excellence in priority areas covering the basic, translational and clinical research landscape to foster personalised medicine programs. Our activities focus on difficult to treat cancers and our teams have dedicated expertise in cancer immunology, the tumour microenvironment, tumor metabolism and neuro-oncology. We explore the cellular and molecular mechanisms of tumor progression using a wide range of state-of-the-art technologies, including multimodal omics technologies (genomics, metabolomics…), advanced immunoprofiling analyses, as well as ex vivo and in vivo imaging modalities leveraging patient data and innovative patient-derived models for cancer research.
Adjunct professor, University of Bergen, Norway
In 2019, Prof Niclou was appointed Director of the Department of Cancer Research at the Luxembourg Institute of Health.
Within the Luxembourg Institute of Health, qualified professionals with various expertises are working together striving for excellence. Their talent, their ability to collaborate and the complementarity of their skills are some of the key elements allowing us to create societal and economical value.
LIH researchers strive to generate meaningful and disease-relevant knowledge and results for patients. Their findings are regularly published in prestigious international peer-reviewed journals, thereby extending the reach and visibility of the institute’s impact.
CANBIO is a doctoral research and training unit (DTU) addressing the clinical problem of tumour progression and recurrence. PhD candidates within CANBIO are engaged in a collaborative and interdisciplinary endeavour to deliver novel insight into tumour escape mechanisms, disease monitoring and large scale data analysis in highly malignant cancers.
TTM is taking a leading role in the coordination of i2TRON, a doctoral training unit (DTU) with a strong focus on developing the new generation of translational scientists, who can turn observations in the laboratory, clinical setting or community into interventions that improve the health of individuals via innovative diagnostics or treatments.
Visit the dedicated webpage for more information: